KR20220070090A - Composition for improving dermatitis comprising extract of Antennaria dioica having antioxidant activity as effective component - Google Patents
Composition for improving dermatitis comprising extract of Antennaria dioica having antioxidant activity as effective component Download PDFInfo
- Publication number
- KR20220070090A KR20220070090A KR1020200156261A KR20200156261A KR20220070090A KR 20220070090 A KR20220070090 A KR 20220070090A KR 1020200156261 A KR1020200156261 A KR 1020200156261A KR 20200156261 A KR20200156261 A KR 20200156261A KR 20220070090 A KR20220070090 A KR 20220070090A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- baekdu
- mugwort
- dermatitis
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 83
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 31
- 241000226574 Antennaria dioica Species 0.000 title claims abstract description 12
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 9
- 206010000496 acne Diseases 0.000 claims abstract description 20
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 19
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 19
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 240000006891 Artemisia vulgaris Species 0.000 claims description 57
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 57
- 239000002537 cosmetic Substances 0.000 claims description 15
- 235000013376 functional food Nutrition 0.000 claims description 14
- 230000036541 health Effects 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 235000017514 Artemisia glacialis Nutrition 0.000 claims 2
- 244000065355 Artemisia glacialis Species 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 17
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 241000894006 Bacteria Species 0.000 abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 230000016396 cytokine production Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 35
- 238000004519 manufacturing process Methods 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 20
- 238000002835 absorbance Methods 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 241000186427 Cutibacterium acnes Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 238000000605 extraction Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- -1 pack Substances 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 239000006210 lotion Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 230000007760 free radical scavenging Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 6
- 229940055019 propionibacterium acne Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000017306 interleukin-6 production Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000021995 interleukin-8 production Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 239000005972 6-Benzyladenine Substances 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- TVZVISCLCBIQRJ-UHFFFAOYSA-N CC1=C(C)SC([N+]2=C(C3=CC=CC(OCC([O-])=O)=C3)N=NN2C(C=C2)=CC=C2S(O)(=O)=O)=N1 Chemical compound CC1=C(C)SC([N+]2=C(C3=CC=CC(OCC([O-])=O)=C3)N=NN2C(C=C2)=CC=C2S(O)(=O)=O)=N1 TVZVISCLCBIQRJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- HOWJQLVNDUGZBI-UHFFFAOYSA-N butane;propane Chemical compound CCC.CCCC HOWJQLVNDUGZBI-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000010639 cypress oil Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000006870 ms-medium Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 항산화 활성을 가지는 백두산떡쑥 추출물을 유효성분으로 함유하는 피부염 개선용 조성물에 관한 것이다.The present invention relates to a composition for improving dermatitis comprising, as an active ingredient, an extract of Mt.
아토피 피부염(atopic dermatitis)은 유전적, 환경적, 면역학적 원인에 의해 발생하고, 피부 가장 바깥에서 보호벽 역할을 하는 각질층에 이상이 생긴 것으로 건조한 기후에서 더욱 심해지는 알레르기 질환이다. 이러한 아토피 피부염의 원인은 주로 유전적인 요소가 많고 면역 반응과 관련되어 있는 것으로 밝혀져 있으며, 그 외에 건조한 피부, 정상인에 비해 쉽게 피부 가려움증을 느끼는 특성, 세균, 바이러스 및 곰팡이 등에 의한 감염, 정서적 요인 및 환경적 요인 등이 서로 복합적으로 작용하여 일어나는 것으로 알려졌다. 아토피 피부염에 동반되는 염증은 과도한 면역세포의 작용으로 인해 종양괴사인자-알파(tumor necrosis factor-α, TNF-α)와 인터루킨-1(interleukin-l, IL-1) 등의 염증성 사이토카인과 활성산소종(reactive oxygen species, ROS)을 대량생산하기 때문에 주변 조직의 손상을 야기한다. 아토피성 피부염에 대한 처방은 주로 스테로이드제, 항히스타민제, 항생제 등과 같은 약물요법이다. 스테로이드제(부신피질호르몬제)는 효과가 우수하지만 장기간 바르면 피부약화, 전신 호르몬증상, 중독성 등의 부작용이 나타날 수 있다. 따라서 아토피성 피부염에 효과가 있으면서도 부작용이 없는 천연물을 이용한 새로운 아토피성 피부염 치료를 위한 조성물 개발이 요구되고 있다.Atopic dermatitis is caused by genetic, environmental, and immunological causes, and is an allergic disease that gets worse in dry climates due to abnormalities in the stratum corneum, which acts as the outermost protective barrier of the skin. The cause of atopic dermatitis has been found to be mainly related to genetic factors and immune response. In addition, dry skin, the characteristic that skin itch easily compared to normal people, infection by bacteria, viruses and fungi, emotional factors and environment It is known that this is caused by a combination of various factors. Inflammation accompanying atopic dermatitis is due to the excessive action of immune cells, inflammatory cytokines and activity such as tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1). Because it mass-produces reactive oxygen species (ROS), it causes damage to surrounding tissues. The prescription for atopic dermatitis is mainly drug therapy such as steroids, antihistamines, and antibiotics. Steroids (adrenal corticosteroids) are effective, but side effects such as skin weakness, systemic hormonal symptoms, and addiction may occur if applied for a long period of time. Therefore, there is a need to develop a new composition for treating atopic dermatitis using a natural product that is effective for atopic dermatitis and has no side effects.
여드름은 모낭 피지선의 염증성 질환으로, 개방성 면포, 구진, 낭종, 결절 등 다양한 피부 병변을 나타낸다. 여드름은 주로 안드로겐 호르몬의 이상 작용에 의해 과도하게 분비된 오일이 모낭에 정체되어 모낭의 입구를 막아 공기의 순환을 차단함으로써 모낭 내부에 상주하는 혐기성 세균이 과도하게 증식하여 발생한다. 특히, 프로피오니박테리움 아크네스(Propionibacterium acnes)는 모낭 내부의 오일 성분들을 탐식하고, 그로 인해 자유지방산을 생산하여 모공을 자극하고 염증을 유발한다고 알려져있다. 세균에 의한 여드름 피부염의 치료에 있어서, 에리스로마이신(erythromycin), 테트라사이틀린(tetracycline), 신다마이신(cindamycine)과 같은 항균 물질들이 주로 사용되어져 왔으나, 이러한 항균 물질은 장기간 사용시 여드름 원인균의 내성, 광과민 작용과 같은 부작용을 야기한다. 이에 대해, 최근에는 식물을 비롯한 천연자원으로부터 인체에 무해하고 부작용이 없으며 강력한 항여드름균 효과를 갖는 유효성분을 탐색하는 연구가 활발하게 진행되고 있다.Acne is an inflammatory disease of the hair follicles and sebaceous glands, and it shows various skin lesions such as open comedones, papules, cysts, and nodules. Acne is mainly caused by excessive growth of anaerobic bacteria residing inside the hair follicles by blocking the air circulation by blocking the entrance of the hair follicles due to excessive secretion of oil due to the abnormal action of androgen hormones in the hair follicles. In particular, it is known that Propionibacterium acnes devours oil components inside hair follicles, thereby producing free fatty acids to stimulate pores and cause inflammation. In the treatment of acne dermatitis caused by bacteria, antibacterial substances such as erythromycin, tetracycline, and cindamycine have been mainly used. cause side effects such as On the other hand, recently, research is being actively conducted to search for active ingredients from natural resources, including plants, that are harmless to the human body, have no side effects, and have a strong anti-acne effect.
백두산떡쑥(Antennaria dioica)은 국화과의 식물로, 우리나라에서는 주로 백두산의 건조한 풀밭에 분포되어 서식하며 중부 및 동부 유럽에서도 서식한다고 알려져있다. 특히, 유럽에서는 이뇨제, 최담제 및 항염증용 등의 민간요법에 사용되어져왔다고 한다. Mt. Baekdu mugwort ( Antennaria dioica ) is a plant in the Asteraceae family. In Korea, it is mainly distributed in the dry grasses of Mt. Baekdu and is known to inhabit in central and eastern Europe. In particular, in Europe, it has been used in folk remedies such as diuretics, aphrodisiacs, and anti-inflammatory drugs.
한편, 한국등록특허 제1747101호에는 'GABA 생산 식물성 유산균을 이용한 혼합 곡류 발효 추출물을 유효성분으로 함유하는 여드름 및 아토피성 피부염 개선용 피부 화장료'가 개시되어 있고, 한국등록특허 제1878069호에는 '생약 혼합물의 추출물과 편백 오일을 함유하는 여드름 또는 아토피 피부염의 예방 또는 치료용 조성물'이 개시되어 있으나, 본 발명의 '항산화 활성을 가지는 백두산떡쑥 추출물을 유효성분으로 함유하는 피부염 개선용 조성물'에 대해서는 기재된 바가 없다.On the other hand, Korean Patent No. 1747101 discloses 'a skin cosmetic for improving acne and atopic dermatitis containing a mixed grain ferment extract using GABA-producing vegetable lactic acid bacteria as an active ingredient', and Korean Patent No. 1878069 discloses 'crude medicine'. Although the 'composition for preventing or treating acne or atopic dermatitis containing the extract of the mixture and cypress oil' is disclosed, the 'composition for improving dermatitis containing the extract of Mt. there is no bar
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명자들은 백두산떡쑥 멀티 슈트 추출물의 항산화 효과를 확인하였고, 우수한 아토피 피부염 또는 여드름 개선 효과를 확인함으로써, 본 발명을 완성하였다.The present invention was derived from the above needs, and the present inventors confirmed the antioxidant effect of the Mt. Baekdu Mt. Mt. mugwort multi-chute extract, and completed the present invention by confirming the excellent atopic dermatitis or acne improvement effect.
상기 과제를 해결하기 위해, 본 발명은 백두산떡쑥(Antennaria dioica) 추출물을 유효성분으로 함유하는 피부염 개선용 화장료 조성물을 제공한다. In order to solve the above problems, the present invention provides a cosmetic composition for improving dermatitis containing an extract of Mt. Baekdu ( Antennaria dioica ) as an active ingredient.
또한, 본 발명은 백두산떡쑥(Antennaria dioica) 추출물을 유효성분으로 함유하는 피부염의 예방 또는 치료용 약학 조성물을 제공한다. In addition, the present invention provides a pharmaceutical composition for preventing or treating dermatitis containing an extract of Mt. Baekdu ( Antennaria dioica ) as an active ingredient.
또한, 본 발명은 백두산떡쑥(Antennaria dioica) 추출물을 유효성분으로 함유하는 피부염 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for improving dermatitis containing an extract of Mt. Baekdu ( Antennaria dioica ) as an active ingredient.
본 발명의 백두산떡쑥 멀티 슈트 추출물은 항산화 활성을 가지며, 염증이 유도된 세포에서의 염증성 사이토카인 생성 감소 효과 및 여드름 원인균이 처리된 세포에서의 염증성 사이토카인 생성 감소 효과가 우수하므로, 아토피 피부염 또는 여드름 개선용 조성물로 매우 유용하게 사용될 수 있을 것으로 기대된다. The Mt. Baekdu Mugwort multi-chute extract of the present invention has antioxidant activity, and has an excellent effect of reducing inflammatory cytokine production in cells induced by inflammation and reducing inflammatory cytokine production in cells treated with acne causative bacteria, so atopic dermatitis or acne It is expected to be very useful as a composition for improvement.
도 1은 백두산떡쑥 멀티 슈트 추출물의 RAW 264.7 세포(A) 및 HaCaT 세포(B)에서의 세포독성을 확인한 결과이다.
도 2는 백두산떡쑥 멀티 슈트 추출물의 DPPH 자유 라디칼 소거능을 확인한 결과이다.
도 3은 백두산떡쑥 멀티 슈트 추출물의 활성 산소 소거능을 확인한 결과이다.
도 4는 LPS로 염증이 유도된 RAW 264.7 세포에서의 백두산떡쑥 멀티 슈트 추출물의 NO 생성 억제능을 확인한 결과이다.
도 5는 LPS로 염증이 유도된 RAW 264.7 세포에서의 백두산떡쑥 멀티 슈트 추출물의 염증성 사이토카인 생성 억제능을 확인한 결과로, A는 TNF-α의 생성량이고, B는 IL-1β의 생성량이며, C는 IL-6의 생성량이다.
도 6은 LPS로 염증이 유도된 RAW 264.7 세포에서의 백두산떡쑥 멀티 슈트 추출물의 PGE2 생성 억제능을 확인한 결과이다.
도 7은 백두산떡쑥 멀티 슈트 추출물의 아토피 피부염 개선 효과를 확인한 결과로, TNF-α및 IFN-γ로 염증이 유도된 HaCaT 세포에서의 IL-6 생성량(A) 및 IL-8 생성량(B)을 나타낸 것이다.
도 8은 백두산떡쑥 멀티 슈트 추출물의 여드름 피부염 개선 효과를 확인한 결과로, 여드름 원인균(Propionibacterium acnes)을 처리한 HaCaT 세포에서의 IL-6 생성량(A) 및 IL-8 생성량(B)을 나타낸 것이다. 1 is a result confirming the cytotoxicity in RAW 264.7 cells (A) and HaCaT cells (B) of the Mt. Baekdu Mt. mugwort multi-chute extract.
Figure 2 is the result of confirming the DPPH free radical scavenging ability of Mt. Baekdu Mt. mugwort multi-chute extract.
3 is a result confirming the active oxygen scavenging ability of the Mt. Baekdu Mt. Mt. mugwort multi-chute extract.
Figure 4 is the result of confirming the NO production inhibitory ability of the extract of Mt. Baekdu Mt. Mugwort multi-chute in RAW 264.7 cells induced by LPS inflammation.
Figure 5 is the result of confirming the inflammatory cytokine production inhibitory ability of the Mt. Baekdu multi-chute extract in RAW 264.7 cells induced by inflammation with LPS, A is the production amount of TNF-α, B is the production amount of IL-1β, C is IL-6 production.
6 is a result confirming the PGE2 production inhibitory ability of the Mt. Baekdu Mt. Mt. mugwort multi-chute extract in RAW 264.7 cells induced by inflammation with LPS.
7 is a result of confirming the atopic dermatitis improvement effect of Mt. Baekdu Mt. mugwort multi-suit extract, IL-6 production (A) and IL-8 production (B) in HaCaT cells induced by inflammation with TNF-α and IFN-γ it has been shown
FIG. 8 shows the IL-6 production amount (A) and IL-8 production amount (B) in HaCaT cells treated with Propionibacterium acnes as a result of confirming the acne dermatitis improvement effect of the Mt. Baekdu Mt. mugwort multi-suit extract.
본 발명의 목적을 달성하기 위하여, 본 발명은 백두산떡쑥(Antennaria dioica) 추출물을 유효성분으로 함유하는 피부염 개선용 화장료 조성물을 제공한다. In order to achieve the object of the present invention, the present invention provides a cosmetic composition for improving dermatitis containing an extract of Mt. Baekdu ( Antennaria dioica ) as an active ingredient.
본 발명에 있어서, 상기 피부염은 아토피 피부염, 여드름, 알레르기 또는 습진 등일 수 있고, 바람직하게는 아토피 피부염 또는 여드름일 수 있으나, 이에 제한되지 않는다. In the present invention, the dermatitis may be atopic dermatitis, acne, allergy or eczema, etc., and preferably may be atopic dermatitis or acne, but is not limited thereto.
본 발명의 피부염 개선용 화장료 조성물에서, 상기 백두산떡쑥 추출물은 백두산떡쑥 멀티 슈트(adventitious shoot) 추출물인 것을 특징으로 하지만 이에 제한하는 것은 아니다. In the cosmetic composition for improving dermatitis of the present invention, the Mt. Baekdu Mugwort extract is characterized in that it is an adventitious shoot extract, but is not limited thereto.
상기 멀티 슈트는 다수의 슈트(묘조)가 발생하여 배양체 자체가 슈트의 덩어리가 된 것을 말하는 것으로, 멀티플 슈트(multiple shoot) 또는 묘조 덩어리(shoot cluster)라고도 하며 캘러스(callus)와는 차이가 있다. 보통 캘러스는 식물의 상처 조직으로부터 형성되는 세포 덩어리로 배지에 첨가되는 생장조절제에 의해 기관형성이나 조직분화를 일으키는 능력을 보유하거나 또는 보유하지 않은 무정형의 세포 덩어리를 말한다. The multi-chute refers to a case in which a plurality of shoots (shootings) are generated and the culture body itself becomes a mass of a chute, which is also called a multiple shoot or a shoot cluster, and is different from a callus. Usually, a callus is a cell mass formed from the wound tissue of a plant, and refers to an amorphous cell mass with or without the ability to induce organogenesis or tissue differentiation by a growth regulator added to the medium.
또한, 상기 백두산떡쑥 추출물의 추출 용매는 당업계에 공지된 통상적인 추출용매를 사용할 수 있다. 바람직한 추출용매로는 DMSO(dimethyl sulfoxide)일 수 있으나, 이에 제한되지 않는다.In addition, as the extraction solvent of the Mt. Baekdu Mt. mugwort extract, a conventional extraction solvent known in the art may be used. A preferred extraction solvent may be dimethyl sulfoxide (DMSO), but is not limited thereto.
상기 백두산떡쑥 추출물의 추출방법은 여과법, 열수 추출, 침지 추출, 환류 냉각 추출 및 초음파 추출 등의 당업계에 공지된 모든 통상적인 방법을 이용하여 추출할 수 있다. 바람직한 추출방법은 초음파 추출이나, 이에 제한되지 않는다. 추출온도는 4~50℃인 것이 바람직하며, 20~30℃인 것이 가장 바람직하나 이에 한정하지 않는다. 또한, 추출시간은 0.5~10시간인 것이 바람직하며, 0.5~5시간이 더욱 바람직하고, 1시간이 가장 바람직하나 이에 한정하지 않는다. The extraction method of the Mt. Baekdu Mt. mugwort extract can be extracted using all conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction. A preferred extraction method is ultrasonic extraction, but is not limited thereto. The extraction temperature is preferably 4 ~ 50 ℃, most preferably 20 ~ 30 ℃, but is not limited thereto. In addition, the extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 5 hours, and most preferably 1 hour, but is not limited thereto.
또한, 상기 백두산떡쑥 추출물은 추출처리에 의해 얻어지는 추출액; 추출액의 희석액 또는 농축액; 추출액을 건조하여 얻어지는 건조물; 조정제물; 또는 정제물 중 어느 하나를 포함할 수도 있다.In addition, the Mt. Baekdu Mt. mugwort extract is an extract obtained by extraction treatment; dilutions or concentrates of extracts; a dried product obtained by drying the extract; modifiers; Or it may include any one of the purified product.
본 발명의 백두산떡쑥 추출물은 피부 세포의 성장을 촉진할 수 있고, 항산화 활성이 우수하며, 염증 유발원에 의한 염증성 사이토카인의 생성을 효과적으로 억제할 수 있고, 여드름 유발균인 프로피오니박테리움 아크네스(Propionibacterium acnes)에 대한 항균 활성을 가지고 있으므로 피부염을 효과적으로 개선시킬 수 있다. The extract of Mt. Baekdu Mt. mugwort extract of the present invention can promote the growth of skin cells, has excellent antioxidant activity, can effectively inhibit the production of inflammatory cytokines caused by inflammatory sources, and can promote acne-causing bacteria, Propionibacterium acnes. Because it has antibacterial activity against ( Propionibacterium acnes ), it can effectively improve dermatitis.
본 발명의 피부염 개선용 화장료 조성물은 크림, 유연화장수, 영양화장수, 팩, 에센스, 헤어토닉, 샴푸, 린스, 헤어 컨디셔너, 헤어 트리트먼트, 젤, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 밀크로션, 모이스처로션, 영양로션, 마사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 영양에센스, 선스크린, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디 로션 및 바디 클렌저로 이루어지는 군으로부터 선택된 어느 하나의 제형을 가질 수 있으나, 이에 제한되지 않는다. 이들 각 제형으로 이루어진 화장료 조성물은 그 제형의 제제화에 필요하고 적절한 각종의 기제와 첨가물을 함유할 수 있으며, 이들 성분의 종류와 양은 당업자에 의해 용이하게 선절될 수 있다. The cosmetic composition for improving dermatitis of the present invention is a cream, softening lotion, nourishing lotion, pack, essence, hair tonic, shampoo, conditioner, hair conditioner, hair treatment, gel, skin lotion, skin softener, skin toner, astringent, milk lotion Any one selected from the group consisting of , moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, nourishing essence, sunscreen, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser It may have a formulation of, but is not limited thereto. The cosmetic composition composed of each of these formulations may contain various bases and additives necessary and appropriate for the formulation of the formulation, and the types and amounts of these components can be easily determined by those skilled in the art.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide as a carrier component etc. may be used.
본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판 부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydro It may contain a propellant such as carbon, propane butane or dimethyl ether.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene fatty acid esters of glycol, 1,3-butylglycol oil, glycerol fatty esters, polyethylene glycol or sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester; Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.
본 발명의 화장료 조성물의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, Fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolin derivative or ethoxylated glycerol fatty acid ester and the like can be used.
또한, 본 발명은 백두산떡쑥 추출물을 유효성분으로 함유하는 피부염의 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating dermatitis containing the Mt. Baekdu Mt. mugwort extract as an active ingredient.
본 발명의 약학 조성물에 있어서, 상기 피부염은 전술한 것과 같다. In the pharmaceutical composition of the present invention, the dermatitis is the same as described above.
본 발명의 피부염의 예방 또는 치료용 약학 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 또는 희석제를 더 포함할 수 있다.The pharmaceutical composition for preventing or treating dermatitis of the present invention may further include an appropriate carrier, excipient or diluent commonly used in the preparation of the pharmaceutical composition.
본 발명에 따른 피부염의 예방 또는 치료용 약학 조성물은 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용 약학조성물을 제공한다. 백두산떡쑥 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 또는 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.The pharmaceutical composition for preventing or treating dermatitis according to the present invention provides a pharmaceutical composition for external use on the skin of a cream, gel, patch, spray, ointment, warning agent, lotion, liniment agent, pasta agent or cataplasma agent. Carriers, excipients or diluents that may be included in the composition comprising the Mt. Baekdu Mt. mugwort extract include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, it is prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
본 발명의 백두산떡쑥 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.0001 내지 100 ㎎/㎏으로, 바람직하게는 0.001 내지 10 ㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the Mt. Baekdu Mt. mugwort extract of the present invention varies depending on the patient's condition and body weight, the degree of disease, drug form, administration route and period, but may be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg/kg per day, preferably 0.001 to 10 mg/kg. Administration may be administered once a day, or may be administered in several divided doses. The above dosage does not limit the scope of the present invention in any way.
또한, 본 발명은 백두산떡쑥 추출물을 유효성분으로 함유하는 피부염 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for improving dermatitis containing the extract of Mt.
본 발명의 건강기능식품 조성물에 있어서, 상기 피부염은 전술한 것과 같다. In the health functional food composition of the present invention, the dermatitis is the same as described above.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The active ingredient may be used appropriately depending on the purpose of its use (prevention or improvement). In general, in the production of food or beverage, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for health purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the type of the health functional food. Examples of foods to which the health functional food composition can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea There are drinks, alcoholic beverages, vitamin complexes, etc., and includes all health foods in the ordinary sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 통상적으로 첨가되는 성분을 포함할 수 있다. 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함시킬 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.In addition, the health functional food composition of the present invention may be prepared as a food, particularly a functional food. The functional food of the present invention may include ingredients that are usually added. Examples include proteins, carbohydrates, fats, nutrients and seasonings. For example, when manufactured as a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates include monosaccharides (eg, glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), oligosaccharides, polysaccharides (eg, dextrin, cyclodextrin, etc.) or sugar alcohols (eg, , xylitol, sorbitol, erythritol, etc.) is preferable. As the flavoring agent, natural flavoring agents (eg, taumartin, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) may be used.
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the health functional food composition, various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonic acid It may further contain a carbonation agent and the like used in beverages. The ratio of these added ingredients is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 이에 한정되는 것은 아니다. Hereinafter, the present invention will be described in detail by way of Examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited thereto.
제조예 1. 백두산떡쑥 멀티 슈트 추출물 제조Preparation Example 1. Preparation of Mt. Baekdu Mt. mugwort multi-chute extract
(1) 백두산떡쑥 멀티 슈트 제조방법(1) Method for manufacturing Baekdusan Mt. mugwort multi-chute
기내 배양을 위한 무균 시료를 확보하기 위해 국내에서 채집한 백두산떡쑥 식물체를 준비하여, 오염 물질을 제거하고 흐르는 물에서 30분~1시간 동안 세척한 후 물기를 제거하였다. 이후, 잎자루(petiole)를 잘라 유리 배양병에 넣고 70%(v/v) 에탄올 용액에서 1분 동안 흔들어 주면서 소독한 후, 멸균수로 1~2회 세척하고 상업용 하이포아염소산나트륨(sodium hypochlorite) 용액을 0.4~0.8%(v/v)로 희석한 용액에 넣고 잘 흔들어 주면서 20분 동안 표면살균을 실시하여 무균 시료를 준비하였다. 표면살균이 이루어진 백두산떡쑥 시료는 살균된 여과지로 남아 있는 수분을 제거한 다음 무균작업대 내에서 가로 세로 1 cm 내외의 적절한 크기로 절취하여 절편들을 준비한 다음 미리 준비한 배양 배지에 10개 씩 3반복으로 치상하여 25℃, 암조건에서 배양하였다. 배양 배지는 MS 배지(Murashige and Skoog, 1962)에 3%(w/v) 수크로스(sucrose), 0.4%(w/v) 겔라이트(gelrite), 0.4 ㎎/ℓ 티아민(thiamine), 100 ㎎/ℓ 미오이노시톨(myo-inositol) 및 식물생장조절제로 2 ㎎/ℓ의 BA(6-benzyladenine)과 0.1 ㎎/ℓ의 NAA(α-naphthaleneacetic acid)가 첨가된 배지를 120℃에서 15분간 멸균 후 사용하였다.In order to secure a sterile sample for in-flight culture, the plants of Mt. Baekdu Mt. Mt. Mt. mugwort collected in Korea were prepared, contaminants were removed, and the water was removed after washing in running water for 30 minutes to 1 hour. After that, cut the petiole, put it in a glass culture bottle, sterilize it by shaking in 70% (v/v) ethanol solution for 1 minute, wash it 1-2 times with sterile water, and use commercial sodium hypochlorite A sterile sample was prepared by putting the solution in a solution diluted to 0.4-0.8% (v/v) and sterilizing the surface for 20 minutes while shaking well. After removing the remaining moisture with sterilized filter paper, the Mt. Baekdu mugwort sample that has been subjected to surface sterilization is cut into an appropriate size of about 1 cm in width and length within a sterile workbench to prepare sections, and then puncture 10 each in 3 repetitions on a previously prepared culture medium. It was cultured at 25°C in dark conditions. The culture medium was MS medium (Murashige and Skoog, 1962) with 3% (w/v) sucrose, 0.4% (w/v) gelrite, 0.4 mg/L thiamine, 100 mg After sterilizing the medium to which 2 mg/L of BA (6-benzyladenine) and 0.1 mg/L of NAA (α-naphthaleneacetic acid) were added as /ℓ myo-inositol and plant growth regulators at 120°C for 15 minutes was used.
백두산떡쑥 식물체 절편 시료들은 배양개시 2주 후부터 조직 절단면에서 팽창이 이루어지면서 줄기로부터 불규칙적인 부정형의 잔가지들이 형성되기 시작하였다. 4주 배양 후에는 다수의 줄기들의 증식과 함께 구조물의 크기 신장이 이루어지면서 크기가 약 5 mm 정도에 이르렀다. 6주 후에는 형성된 다수의 멀티 슈트들이 더욱 증식이 활발해지는 것을 관찰하였다. 상기 멀티 슈트는 동일 조성의 새로운 배지에 4주 주기로 계대배양하여 백두산떡쑥 줄기 유래 식물세포를 확보하였다(KCTC PC3081).From 2 weeks after the initiation of culture, the plant section samples from Mt. Baekdu Mt. Modley were expanded at the tissue cut surface, and irregular amorphous twigs began to form from the stem. After 4 weeks of incubation, the size of the structure increased with the proliferation of a number of stems, and the size reached about 5 mm. After 6 weeks, it was observed that the multi-chute formed more actively proliferate. The multi-chute was subcultured in a new medium of the same composition at a cycle of 4 weeks to obtain plant cells derived from Mt. Baekdu Mt. mugwort stem (KCTC PC3081).
(2) 백두산떡숙 멀티 슈트 추출물 제조방법(2) Method for manufacturing Baekdusan rice cake soup multi-chute extract
상기 방법으로 제조된 백두산떡쑥 멀티 슈트 건조분말 100 ㎎에 DMSO(dimethyl sulfoxide) 1 ㎖을 첨가한 후 실온(25±5℃)에서 1시간 동안 초음파 처리하여 얻은 추출물을 1,2000 rpm으로 5분 동안 원심분리한 후 상등액을 취해 실험에 사용하였다. After adding 1 ml of dimethyl sulfoxide (DMSO) to 100 mg of 100 mg of Mt. Baekdu Mugwort multi-chute dry powder prepared by the above method, the extract obtained by ultrasonication at room temperature (25±5° C.) for 1 hour was incubated at 1,2000 rpm for 5 minutes. After centrifugation, the supernatant was taken and used for the experiment.
실시예 1. 백두산떡쑥 멀티 슈트 추출물의 세포독성 분석Example 1. Cytotoxicity analysis of Mt. Baekdu Mt. mugwort multi-chute extract
마우스 대식세포주인 RAW 264.7 세포는 한국세포주은행(Korea Cell Line Bank, KCLB, No. 40071)에서 분양받아 사용하였으며, 10% FBS(fetal bovine serum, GE Healthcare Life Sciences, USA)가 함유된 DMEM(Dulbecco Modified Eagle Medium, Welgene, Korea) 배지를 사용하여 37℃, 5% CO2 항온기에서 배양하였고, 3일에 한 번씩 계대배양을 수행하였다. RAW 264.7 세포를 5×103 cells/웰로 96 웰 플레이트에 분주하여 24시간 동안 배양하여 안정화한 후, 혈청이 결핍된 DMEM 배지로 희석한 50, 100, 250 및 500 ㎍/㎖의 백두산떡쑥 멀티 슈트 추출물을 각 웰에 100 ㎕씩 넣고 24시간 배양하였다. 배양액을 제거하고 5 mg/㎖의 MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)를 각 웰에 넣고 4시간 동안 배양한 후, 상등액을 제거하고 DMSO(dimethyl sulfoxide)를 100 ㎕씩 분주하여 각 웰에 생성된 결정체를 모두 용해시키고, 마이크로플레이트 리더기(Multiskan Go, Thermo Scientific, USA)를 이용하여 570 nm에서 흡광도를 측정하였고, 하기 계산식을 통해 세포생존율을 분석하였다. RAW 264.7 cells, a mouse macrophage cell line, were purchased from Korea Cell Line Bank (KCLB, No. 40071) and used, and DMEM (Dulbecco) containing 10% FBS (fetal bovine serum, GE Healthcare Life Sciences, USA) was used. Modified Eagle Medium, Welgene, Korea) medium was used and cultured at 37° C., 5% CO 2 incubator, and subculture was performed once every 3 days. RAW 264.7 cells were dispensed in a 96-well plate at 5×10 3 cells/well, cultured for 24 hours, and stabilized, followed by 50, 100, 250 and 500 μg/ml Baekdusan Mt. mugwort multi-chute diluted with serum-deficient DMEM medium 100 μl of the extract was added to each well and incubated for 24 hours. Remove the culture medium, add 5 mg/ml of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to each well, incubate for 4 hours, remove the supernatant and DMSO ( 100 μl of dimethyl sulfoxide) was dispensed to dissolve all the crystals in each well, absorbance was measured at 570 nm using a microplate reader (Multiskan Go, Thermo Scientific, USA), and the cell viability was calculated using the following formula. analyzed.
세포생존율(%)=[시료처리군의 흡광도/대조군의 흡광도]X100Cell viability (%) = [absorbance of sample treatment group / absorbance of control group]
인간각질형성세포주 HaCaT 세포는 CLS에서 분양받아 사용하였으며, 10% FBS(fetal bovine serum, GE Healthcare Life Sciences, USA)가 함유된 DMEM(Dulbecco Modified Eagle Medium, Welgene, Korea) 배지를 사용하여 37℃, 5% CO2 항온기에서 배양하였고, 3일에 한 번씩 계대배양을 수행하였다. HaCaT 세포를 5×103 cells/웰로 96 웰 플레이트에 분주하여 24시간 동안 배양하여 안정화한 후, 혈청이 결핍된 DMEM 배지로 희석한 50, 100, 250 및 500 ㎍/㎖의 백두산떡쑥 멀티 슈트 추출물을 각 웰에 100 ㎕씩 넣어 24시간 배양하였다. 배양액을 제거하고 20 ㎕의 MTS(4,5-dimethylthiazol-2-yl-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)를 각 웰에 넣고 4시간 동안 배양한 후, 마이크로플레이트 리더기(Multiskan Go, Thermo Scientific, USA)를 이용하여 490 nm에서 흡광도를 측정하였고, 하기 계산식을 통해 세포생존율을 분석하였다. HaCaT cells, a human keratinocyte line, were purchased from CLS and used at 37°C using DMEM (Dulbecco Modified Eagle Medium, Welgene, Korea) medium containing 10% FBS (fetal bovine serum, GE Healthcare Life Sciences, USA). Incubated in a 5% CO 2 incubator, subculture was performed once every 3 days. HaCaT cells were dispensed in a 96-well plate at 5×10 3 cells/well, cultured for 24 hours to stabilize, and then, 50, 100, 250 and 500 μg/ml Baekdusan Mossack mugwort multi-chute extract diluted with serum-deficient DMEM medium. was put into each well of 100 μl and incubated for 24 hours. After removing the culture medium, 20 μl of MTS (4,5-dimethylthiazol-2-yl-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) was added to each well and incubated for 4 hours. , the absorbance was measured at 490 nm using a microplate reader (Multiskan Go, Thermo Scientific, USA), and the cell viability was analyzed using the following formula.
세포생존율(%)=[시료처리군의 흡광도/대조군의 흡광도]X100Cell viability (%) = [absorbance of sample treatment group / absorbance of control group]
그 결과, 50, 100, 250 및 500 ㎍/㎖의 백두산떡쑥 멀티 슈트 추출물은 RAW 264.7 세포 및 HaCaT 세포에서 세포독성을 나타내지 않는 것을 확인하였다(도 1). As a result, it was confirmed that 50, 100, 250 and 500 ㎍ / ㎖ of Mt. Baekdu Mugwort multi-chute extract did not show cytotoxicity in RAW 264.7 cells and HaCaT cells (FIG. 1).
실시예 2. 백두산떡쑥 멀티 슈트 추출물의 항산화 활성 분석Example 2. Analysis of Antioxidant Activity of Mt. Baekdu Mt. Artemisia Multi-chute Extract
(1) 자유 라디칼 소거능 측정(1) Measurement of free radical scavenging ability
백두산떡쑥 멀티 슈트 추출물의 자유 라디칼(free radical) 소거능은 DPPH를 이용하여 분석하였다. 먼저 DPPH(1,1-diphenyl-2-picrylhydrazyl)를 에탄올에 용해하여 0.1 mM DPPH 용액을 준비하고, 에탄올로 희석한 10, 100, 250 및 500 ㎍/㎖의 백두산떡쑥 멀티 슈트 추출물을 준비하였다. 각 농도의 백두산떡쑥 멀티 슈트 추출물과 0.1 mM DPPH 용액을 1:1로 섞어 96 웰 플레이트에 처리하고 37℃에서 30분 동안 반응시킨 다음, 517 nm에서 흡광도를 측정하고 하기 계산식을 통해 자유 라디칼 소거능을 산출하였다.The free radical scavenging ability of the Mt. Baekdu Mt. mugwort multi-chute extract was analyzed using DPPH. First, a 0.1 mM DPPH solution was prepared by dissolving DPPH (1,1-diphenyl-2-picrylhydrazyl) in ethanol, and 10, 100, 250, and 500 μg/ml of Baekdusan-Mountain Mossack mugwort multi-chute extract diluted with ethanol was prepared. Mt. Baekdu Mugwort multi-chute extract of each concentration and 0.1 mM DPPH solution were mixed 1:1, treated in a 96-well plate, reacted at 37°C for 30 minutes, absorbance was measured at 517 nm, and free radical scavenging ability was calculated using the following formula. calculated.
DPPH 자유 라디칼 소거능(%) =｛1-(A-B/C)}X100DPPH free radical scavenging capacity (%) = {1-(A-B/C)}X100
A : 시료와 DPPH를 반응시킨 후의 흡광도 A: Absorbance after reacting the sample with DPPH
B : 시료와 에탄올을 반응시킨 후의 흡광도 B: Absorbance after reacting the sample with ethanol
C : 에탄올과 DPPH를 반응시킨 후의 흡광도(blank)C: Absorbance (blank) after reacting ethanol and DPPH
그 결과, 백두산떡쑥 멀티 슈트 추출물에 의한 자유 라디칼 소거능이 농도 의존적으로 증가하는 것을 확인하였다(도 2). As a result, it was confirmed that the free radical scavenging ability of the Mt. Baekdu Mt. mugwort multi-chute extract increased in a concentration-dependent manner (FIG. 2).
(2) 활성산소 소거능 측정(2) Measurement of active oxygen scavenging ability
백두산떡쑥 멀티 슈트 추출물의 활성산소 소거능은 SOD(Superoxide dismutase) 측정 키트를 이용하여 분석하였다. 10, 100, 250 및 500 ㎍/㎖의 백두산떡쑥 멀티 슈트 추출물을 준비한 다음, 키트 내의 반응액에 섞어 96 웰 플레이트에 넣고 37℃에서 20분간 반응시켰다. 이후, 450 nm 파장에서 흡광도를 측정하고, 하기 계산식을 통해 활성산소 소거능을 산출하였다.The active oxygen scavenging ability of the Mt. Baekdu Mt. mugwort multi-chute extract was analyzed using a superoxide dismutase (SOD) measurement kit. 10, 100, 250, and 500 μg/ml of Mt. Baekdu Mugwort multi-chute extract were prepared, mixed with the reaction solution in the kit, placed in a 96-well plate, and reacted at 37° C. for 20 minutes. Then, absorbance was measured at a wavelength of 450 nm, and the active oxygen scavenging ability was calculated through the following formula.
활성산소 소거능(%) = {[(C-D)-A-B)]/(C-D)}x100Free radical scavenging ability (%) = {[(C-D)-A-B)]/(C-D)}x100
A : 시료와 반응액을 반응시킨 후의 흡광도A: Absorbance after reacting the sample with the reaction solution
B : 시료와 WST Working Solution을 반응시킨 후의 흡광도 B: Absorbance after reacting the sample with WST Working Solution
C : 반응액의 흡광도 C: absorbance of the reaction solution
D : WST Working Solution의 흡광도D : Absorbance of WST Working Solution
그 결과, 백두산떡쑥 멀티 슈트 추출물에 의한 활성산소 소거능이 농도 의존적으로 증가하는 것을 확인하였다(도 3).As a result, it was confirmed that the active oxygen scavenging ability of the Mt. Baekdu Mt. Mt. mugwort multi-chute extract increased in a concentration-dependent manner (FIG. 3).
상기 결과를 통해 백두산떡쑥 멀티 슈트 추출물이 우수한 항산화 활성이 있음을 알 수 있었다. From the above results, it was found that the Mt. Baekdu Mt. mugwort multi-chute extract had excellent antioxidant activity.
실시예 3. 백두산떡쑥 멀티 슈트 추출물의 항염 활성 분석Example 3. Analysis of anti-inflammatory activity of Mt. Baekdu Mt. mugwort multi-chute extract
LPS(lipopolysaccharide)로 염증이 유도된 마우스 대식세포주인 RAW 264.7 세포에서의 백두산떡쑥 멀티 슈트 추출물의 항염 활성을 분석하였다. The anti-inflammatory activity of the Mt. Baekdu Mugwort multi-chute extract was analyzed in RAW 264.7 cells, a mouse macrophage cell line induced by lipopolysaccharide (LPS).
(1) NO 생성 억제능 측정(1) Measurement of NO production inhibitory ability
NO(nitric oxide)는 면역계에서 방어분자로서 중요한 역할을 하지만, 과도하게 증가하면 NO를 생성하는 세포자신과 주위의 세포와 조직, 기관에 손상을 초래하여 면역질환을 포함한 관절염, 기관지염, 다발성 경화증과 같은 병적반응을 일으킨다. 따라서, 백두산떡쑥 멀티 슈트 추출물의 항염 활성을 분석하기 위하여 NO 생성 억제능을 측정하였다. RAW 264.7 세포를 5×104 cells/웰로 24 웰 플레이트에 분주하여 24 시간 동안 배양하여 안정화한 후, 혈청이 결핍된 DMEM 배지로 희석한 50, 100, 250 및 500 ㎍/㎖의 백두산떡쑥 멀티 슈트 추출물 2시간 동안 전처리한 다음 LPS(1 ㎍/㎖)를 처리하여 24시간 동안 배양하였다. 생성된 NO의 양은 그리스 시약(Griess Reagent System, Promega, USA)을 이용하여 세포배양액 중에 존재하는 NO2 -의 형태로 측정하였다. 세포배양 상등액 50 ㎕에 그리스 시약 100 ㎕를 처리하고 30분 내에 540 nm 파장에서 흡광도를 측정하였다.NO (nitric oxide) plays an important role as a defense molecule in the immune system, but when it is excessively increased, it causes damage to the cells themselves and surrounding cells, tissues, and organs that produce NO. cause the same pathological reaction. Therefore, in order to analyze the anti-inflammatory activity of the Mt. Baekdu Mt. mugwort multi-chute extract, the NO production inhibitory ability was measured. RAW 264.7 cells were dispensed in a 24-well plate at 5×10 4 cells/well, incubated for 24 hours, and stabilized, followed by 50, 100, 250 and 500 μg/ml Baekdusan Mt. mugwort multi-chute diluted with serum-deficient DMEM medium. The extract was pre-treated for 2 hours and then treated with LPS (1 μg/ml) and incubated for 24 hours. The amount of NO generated was measured in the form of NO 2 − present in the cell culture medium using a grease reagent (Griess Reagent System, Promega, USA). 50 μl of the cell culture supernatant was treated with 100 μl of grease reagent, and absorbance was measured at 540 nm wavelength within 30 minutes.
그 결과, LPS 단독 처리군의 NO 생성량은 대조군 대비 현저하게 증가하였고, 백두산떡쑥 멀티 슈트 추출물 처리군의 NO 생성량은 감소하였으며 특히, 500 ㎍/㎖의 백두산떡쑥 멀티 슈트 추출물 처리군은 LPS 단독 처리군 대비 약 83% 가량의 NO 생성 억제능을 보이는 것을 확인하였다(도 4).As a result, the NO production of the LPS-only treatment group was significantly increased compared to the control group, and the NO production of the Baekdusan Mt. mugwort multi-chute extract treatment group decreased. It was confirmed that the NO production inhibitory ability of about 83% compared to that (FIG. 4).
(2) 염증성 사이토카인의 생성 억제능 측정(2) Measurement of the ability to inhibit the production of inflammatory cytokines
RAW 264.7 세포를 5×104 cells/웰로 24 웰 플레이트에 분주하여 24시간 동안 배양하여 안정화한 후, 혈청이 결핍된 DMEM 배지로 희석한 50, 100, 250 및 500 ㎍/㎖의 백두산떡쑥 멀티 슈트 추출물을 2시간 동안 전처리한 다음 LPS(1 ㎍/㎖)를 처리하여 24시간 동안 배양하였다. 이후, 12,000 rpm으로 3분간 원심분리하여 얻어진 상층액으로 염증성 사이토카인 TNF-α(tumor necrosis factor alpha), IL-1β(Interleukin 1 beta) 및 IL-6(Interleukin 6)의 생성량을 측정하였다. 각 사이토카인은 ELISA 키트(R&D systems Inc., USA)를 이용하여 정량하였으며 standard에 대한 표준곡선 R2 값이 0.9 이상이었다. RAW 264.7 cells were dispensed in a 24-well plate at 5×10 4 cells/well, cultured for 24 hours, and stabilized, followed by 50, 100, 250 and 500 μg/ml Baekdusan Mt. mugwort multi-chute diluted with serum-deficient DMEM medium. The extract was pretreated for 2 hours and then treated with LPS (1 μg/ml) and incubated for 24 hours. Then, the amount of inflammatory cytokines TNF-α (tumor necrosis factor alpha), IL-1β (
그 결과, LPS 단독 처리군은 대조군 대비 TNF-α, IL-1β 및 IL-6 사이토카인 생성량이 현저하게 증가하였고, 백두산떡쑥 멀티 슈트 추출물 처리군의 염증성 사이토카인 생성량은 농도 의존적으로 감소하는 것을 확인하였다(도 5).As a result, it was confirmed that the LPS-only treatment group significantly increased the production of TNF-α, IL-1β, and IL-6 cytokines compared to the control group, and the amount of inflammatory cytokine production of the Mt. was done (FIG. 5).
(3) PGE2 생성 억제능 측정(3) PGE2 production inhibitory ability measurement
RAW 264.7 세포를 5×104 cells/웰로 24 웰 플레이트에 분주하여 24시간 동안 배양하여 안정화한 후, 혈청이 결핍된 DMEM 배지로 희석한 50, 100, 250 및 500 ㎍/㎖의 백두산떡쑥 멀티 슈트 추출물을 2시간 동안 전처리한 다음 LPS(1 ㎍/㎖)를 처리하여 24시간 동안 배양하였다. 이후, 12,000 rpm으로 3분간 원심분리하여 얻어진 상층액으로 Prostaglandin E2(PGE2)의 생성량을 측정하였다. ELISA 키트(R&D systems Inc., USA)를 이용하여 정량하였으며 standard에 대한 표준곡선 R2 값이 0.9 이상이었다. RAW 264.7 cells were dispensed in a 24-well plate at 5×10 4 cells/well, cultured for 24 hours, and stabilized, followed by 50, 100, 250 and 500 μg/ml Baekdusan Mt. mugwort multi-chute diluted with serum-deficient DMEM medium. The extract was pretreated for 2 hours and then treated with LPS (1 μg/ml) and incubated for 24 hours. Thereafter, the production amount of Prostaglandin E2 (PGE2) was measured with the supernatant obtained by centrifugation at 12,000 rpm for 3 minutes. It was quantified using an ELISA kit (R&D systems Inc., USA), and the standard curve R 2 value for the standard was 0.9 or more.
그 결과, LPS 단독 처리군은 대조군 대비 PGE2 생성량이 현저하게 증가하였고, 백두산떡쑥 멀티 슈트 추출물 처리군의 PGE2의 생성량은 농도의존적으로 감소하는 것을 확인하였다(도 6).As a result, the LPS alone treatment group significantly increased the amount of PGE2 production compared to the control group, and it was confirmed that the amount of PGE2 production in the group treated with the Mt. Baekdu Mt. Tteokbokki multi-chute extract decreased in a concentration-dependent manner (FIG. 6).
이상의 결과를 통해 본 발명의 백두산떡쑥 멀티 슈트 추출물이 우수한 항염 효과가 있음을 확인할 수 있었다. Through the above results, it was confirmed that the Mt. Baekdu Mt. mugwort multi-chute extract of the present invention has an excellent anti-inflammatory effect.
실시예 4. 백두산떡쑥 멀티 슈트 추출물의 아토피 피부염 개선 효과 분석Example 4. Analysis of the improvement effect of atopic dermatitis of Mt. Baekdu Mt. mugwort multi-suit extract
피부 손상으로 인해 사이토카인이 만성적으로 생성되면 피부 건조를 유발시켜 아토피 피부염과 같은 피부질환을 일으키게 된다. 이에 TNF-α및 IFN-γ로 염증이 유도된 인간각질형성세포주인 HaCaT 세포에서의 백두산떡쑥 멀티 슈트 추출물의 아토피 피부염 개선 효과를 확인하였다. HaCaT 세포를 1×105 cells/웰 농도로 24 웰 플레이트에 분주하여 24시간 동안 배양하여 안정화한 후, 혈청이 결핍된 DMEM 배지로 희석한 50, 100, 250 및 500 ㎍/㎖의 백두산떡쑥 멀티 슈트 추출물을 4시간 동안 전처리한 다음 TNF-α(10 ng/㎖) 와 IFN-γ(10 ng/㎖)를 동시에 처리하여 18시간 동안 배양하였다. 이후, 12,000 rpm으로 3분간 원심분리하여 얻어진 상층액으로 염증성 사이토카인 IL-6 및 IL-8의 생성량을 측정하였다. 염증성 사이토카인은 ELISA 키트(BD Pharmingen, USA)를 이용하여 정량하였으며 standard에 대한 표준곡선 R2 값이 0.9 이상이었다. When cytokines are produced chronically due to skin damage, it causes skin dryness and causes skin diseases such as atopic dermatitis. Accordingly, it was confirmed that the atopic dermatitis improvement effect of Mt. Baekdu Mugwort multi-chute extract in HaCaT cells, a human keratinocyte line induced by inflammation with TNF-α and IFN-γ. HaCaT cells were dispensed in a 24-well plate at a concentration of 1×10 5 cells/well, cultured for 24 hours, and stabilized. The shoot extract was pre-treated for 4 hours and then treated with TNF-α (10 ng/ml) and IFN-γ (10 ng/ml) at the same time and cultured for 18 hours. Thereafter, the amount of production of inflammatory cytokines IL-6 and IL-8 was measured with the supernatant obtained by centrifugation at 12,000 rpm for 3 minutes. Inflammatory cytokines were quantified using an ELISA kit (BD Pharmingen, USA), and the standard curve R 2 value for the standard was 0.9 or more.
그 결과, 백두산떡쑥 멀티 슈트 추출물에 의해 IL-6 및 IL-8의 생성량이 농도 의존적으로 감소하는 것을 확인하였다(도 7). As a result, it was confirmed that the production amount of IL-6 and IL-8 was decreased in a concentration-dependent manner by the Mt. Baekdu Mt. mugwort multi-chute extract (FIG. 7).
이를 통해, 본 발명의 백두산떡쑥 멀티 슈트 추출물이 사이토카인의 만성적 생성에 의한 아토피 피부염을 개선할 수 있음을 알 수 있었다. Through this, it was found that the Mt. Baekdu Mt. mugwort multi-chute extract of the present invention can improve atopic dermatitis caused by the chronic production of cytokines.
실시예 5. 백두산떡쑥 멀티 슈트 추출물의 여드름 피부염 개선 효과 분석Example 5. Analysis of the effect of improving acne dermatitis of Mt. Baekdu Mt. mugwort multi-suit extract
프로피오니박테리움 아크네스(Propionibacterium acnes, KCTC 6919)는 여드름 피부염을 유발하는 주요한 균으로, 피부에서 과잉 생산된 피지에 의해 막힌 모낭 내에서 증식하며, 피부 내의 단핵구를 활성화시키고 염증성 사이토카인의 분비를 촉진한다. P. acnes를 BHI(brain heart infusion) 배지에 접종하여, 37℃의 혐기 조건으로 600 nm에서의 흡광도가 1.0이 될 때까지 액체배지에서 배양한 후 상등액을 회수하여 5,000 rpm, 4℃에서 15분 동안 원심분리 후 다시 멸균된 PBS로 2회 세척하였다. P. acnes를 80℃ 에서 30분간 처리하여 사멸시킨 후 실험에 사용하였다. Propionibacterium acnes ( KCTC 6919) is a major bacterium that causes acne dermatitis, proliferates in hair follicles blocked by excess sebum in the skin, activates monocytes in the skin, and inhibits the secretion of inflammatory cytokines. promote P. acnes was inoculated in BHI (brain heart infusion) medium and cultured in a liquid medium until the absorbance at 600 nm became 1.0 under anaerobic conditions at 37°C, and then the supernatant was recovered and the supernatant was recovered at 5,000 rpm, 4°C for 15 minutes. After centrifugation for a while, it was washed twice with sterile PBS again. P. acnes was treated and killed at 80° C. for 30 minutes, and then used in the experiment.
(1) 염증성 사이토카인 생성 억제 억제능 측정(1) Measurement of inhibitory ability to inhibit inflammatory cytokine production
HaCaT 세포를 1×105 cells/웰 농도로 24 웰 플레이트에 분주하여 24시간 동안 배양하여 안정화한 후, 혈청이 결핍된 DMEM 배지로 희석한 50, 100, 250 및 500 ㎍/㎖의 백두산떡쑥 멀티 슈트 추출물을 4시간 동안 전처리한 후, P. acnes를 처리하여 18시간 동안 배양하였다. 이후, 12,000 rpm으로 3분간 원심분리하여 얻어진 상층액으로 염증성 사이토카인 IL-6 및 IL-8의 생성량을 측정하였다. 염증성 사이토카인은 ELISA 키트(BD Pharmingen, USA)를 이용하여 정량하였으며 standard에 대한 표준곡선 R2 값이 0.9 이상이었다. HaCaT cells were dispensed in a 24-well plate at a concentration of 1×10 5 cells/well, cultured for 24 hours, and stabilized. After pre-treatment of the chute extract for 4 hours, P. acnes was treated and cultured for 18 hours. Thereafter, the amount of production of inflammatory cytokines IL-6 and IL-8 was measured with the supernatant obtained by centrifugation at 12,000 rpm for 3 minutes. Inflammatory cytokines were quantified using an ELISA kit (BD Pharmingen, USA), and the standard curve R 2 value for the standard was 0.9 or more.
그 결과, P. acnes 단독 처리군은 대조군 대비 IL-6 및 IL-8의 생성량이 현저하게 증가하였고, 백두산떡쑥 멀티 슈트 추출물 처리군의 염증성 사이토카인 생성량은 농도 의존적으로 감소하는 것을 확인하였다(도 8).As a result, the P. acnes alone treatment group significantly increased the production of IL-6 and IL-8 compared to the control group, and it was confirmed that the amount of inflammatory cytokine production in the Mt. Baekdu multi-chute extract treated group decreased in a concentration-dependent manner (Fig. 8).
(2) 항균 활성 측정(2) Measurement of antibacterial activity
평판배지에 배양된 P. acnes 균주를 백금이로 취하여 BHI 액체배지 5 ㎖에 현탁한 후, 24시간 동안 배양하였다. 이를 다시 평판배지에 100 ㎕ 분주하여 스프레더(spreader)로 균일하게 도말하였다. 페이퍼 디스크(paper disc, 8 mm. ADVANTEC, Japan)에 백두산떡쑥 멀티 슈트 추출물을 1 ㎎/디스크, 2 ㎎/디스크 및 3 ㎎/디스크로 점적하여 P. acnes 균주가 도말된 상기 평판배지 위에 올려놓고 37℃에서 24시간 동안 배양한 후, 생육 저지환(clear zone)의 직경을 측정하여 항균 활성을 확인하였다. The P. acnes strain cultured on a plate medium was taken as platinum lice, suspended in 5 ml of BHI liquid medium, and then cultured for 24 hours. 100 μl of this was again dispensed on a plate medium and spread evenly with a spreader. A paper disc (8 mm. ADVANTEC, Japan) of Mt. Baekdu Mugwort multi-chute extract was dripped at 1 mg/disk, 2 mg/disc and 3 mg/disc, and placed on the plate medium on which the P. acnes strain was smeared. After culturing at 37° C. for 24 hours, the diameter of the growth stop ring (clear zone) was measured to confirm the antibacterial activity.
그 결과, 백두산떡쑥 멀티 슈트 추출물은 1 ㎎/디스크 및 2 ㎎/디스크에서는 생육 저지환이 나타나지 않았으나, 3 ㎎/디스크에서는 직경 12mm의 생육 저지환을 확인함으로써 백두산떡쑥 멀티 슈트 추출물은 P. acnes에 대한 항균 효과가 있음을 알 수 있었다(표 1). As a result, in the case of the Baekdusan mugwort multi-chute extract, growth-stopping rings did not appear at 1 mg/disk and 2 mg/disk, but at 3 mg/disk, by confirming the growth-stopping rings with a diameter of 12 mm, the It was found that there was an antibacterial effect (Table 1).
이상의 결과를 통해, 본 발명의 백두산떡쑥 멀티 슈트 추출물이 프로피오니박테리움 아크네스(P. acnes)에 의한 여드름 피부염을 개선할 수 있음을 알 수 있었다. Through the above results, the multi-chute extract of Mt. Baekdu wormwood of the present invention is acne caused by Propionibacterium acnes ( P. acnes ) It was found that dermatitis can be improved.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200156261A KR102406982B1 (en) | 2020-11-20 | 2020-11-20 | Composition for improving dermatitis comprising extract of Antennaria dioica having antioxidant activity as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200156261A KR102406982B1 (en) | 2020-11-20 | 2020-11-20 | Composition for improving dermatitis comprising extract of Antennaria dioica having antioxidant activity as effective component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220070090A true KR20220070090A (en) | 2022-05-30 |
| KR102406982B1 KR102406982B1 (en) | 2022-06-09 |
Family
ID=81796621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200156261A KR102406982B1 (en) | 2020-11-20 | 2020-11-20 | Composition for improving dermatitis comprising extract of Antennaria dioica having antioxidant activity as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102406982B1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050008233A (en) * | 2003-07-14 | 2005-01-21 | 고운맘 | Additive for medicine containing mugwort essential oil and mugwort prolysis essence |
| KR20140126942A (en) * | 2013-04-24 | 2014-11-03 | 스킨큐어(주) | Composition for treatment and prevention of inflammatory skin diseases comprising Gnaphalium affine D. Don extract |
| KR20160128589A (en) * | 2015-04-29 | 2016-11-08 | 스킨큐어(주) | A composition for improving inflammatory skin diseases containing natural extracts |
| JP2017043575A (en) * | 2015-08-28 | 2017-03-02 | 北海道三井化学株式会社 | Skin external preparation |
-
2020
- 2020-11-20 KR KR1020200156261A patent/KR102406982B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050008233A (en) * | 2003-07-14 | 2005-01-21 | 고운맘 | Additive for medicine containing mugwort essential oil and mugwort prolysis essence |
| KR20140126942A (en) * | 2013-04-24 | 2014-11-03 | 스킨큐어(주) | Composition for treatment and prevention of inflammatory skin diseases comprising Gnaphalium affine D. Don extract |
| KR20160128589A (en) * | 2015-04-29 | 2016-11-08 | 스킨큐어(주) | A composition for improving inflammatory skin diseases containing natural extracts |
| JP2017043575A (en) * | 2015-08-28 | 2017-03-02 | 北海道三井化学株式会社 | Skin external preparation |
Non-Patent Citations (1)
| Title |
|---|
| COS IN. 2020 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102406982B1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102348042B1 (en) | Composition for improving skin condition comprising extract of hydrangea serrata | |
| KR101302222B1 (en) | Mixed vegetable extracts for preventing, improving and treating atopic dermatitis and allergic skin diseases, composition including the same and method of producing the same | |
| KR101934794B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising extract mixture of Diospyros lotus leaf and grape fruit stem as effective component | |
| KR20240004199A (en) | Antibacterial composition containing extract or fractions of Prunus pendula for. ascendens | |
| KR101894807B1 (en) | Antimicrobial composition containing Rosa davurica extract as effective component | |
| KR102334546B1 (en) | Composition for anti-inflammatory comprising male pupa extract | |
| KR102070789B1 (en) | Composition for ameliorating or treating acne comprising Salvia plebeia extract and its fraction as effective component | |
| KR102142461B1 (en) | Composition for improving skin condition comprising extract of korean fir | |
| KR102406982B1 (en) | Composition for improving dermatitis comprising extract of Antennaria dioica having antioxidant activity as effective component | |
| KR102526287B1 (en) | Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component | |
| KR101889331B1 (en) | A composition having anti-oxidation, anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
| KR101213054B1 (en) | Composition for the prevention and treatment of apotic dermatitis containing the mixed extract of Chrysanthemum indicum Linne. and steamed Rheum undulatum with alcohol as an effective ingredient | |
| KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
| KR102448072B1 (en) | Composition for improving dermatitis comprising extract of Weigela subsessilis having antioxidant activity as effective component | |
| KR20180017974A (en) | Cosmetic composition for preventing or treating acne comprising combined herbal extracts | |
| KR101826823B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising extract mixture of Pleurotus eryngii and grape branch as effective component | |
| KR101797843B1 (en) | A composition having anti-inflammation or anti-bacterial activity comprising Acanthopanax koreanum Nakai stem extracts, fractions thereof or compounds isolated therefrom as an active ingredient | |
| KR20220070095A (en) | Composition for improving skin wrinkle and dermatitis comprising extract of Cedrela sinensis having antioxidant activity as effective component | |
| KR102561258B1 (en) | Composition for controlling sebum and improving pore comprising Jasminum Officinale, Salix Alba (willow) bark and Solanum melogena fruit extract | |
| KR101769123B1 (en) | Cosmetic composition containing natural complex extract for improving atopic dermatitis | |
| KR20200134657A (en) | Anti-inflammation Compound derived from Yuja and Isolating Method Thereof | |
| KR102604076B1 (en) | Composition for anti-inflammation and skin regeneration comprising extract of Syringa oblata as effective component | |
| KR102403229B1 (en) | Composition for improving skin containing Moringa extract and Opuntia humifusa extract thereof as an active ingredient | |
| KR102406981B1 (en) | Composition for improving skin wrinkle comprising extract of Semiaquilegia adoxoides having antioxidant and anti-inflammatory activity as effective component | |
| KR102411893B1 (en) | Composition for inhibiting sebum secretion comprising Chestnut bur extract as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |